761 Shares in Eli Lilly and Company (NYSE:LLY) Purchased by HTLF Bank

HTLF Bank acquired a new stake in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 761 shares of the company’s stock, valued at approximately $444,000.

Other institutional investors also recently modified their holdings of the company. Lipe & Dalton bought a new stake in Eli Lilly and Company during the 4th quarter worth about $26,000. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company during the third quarter worth approximately $27,000. Retirement Group LLC raised its stake in shares of Eli Lilly and Company by 159.1% during the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after buying an additional 35 shares during the last quarter. Cornerstone Planning Group LLC acquired a new position in Eli Lilly and Company in the second quarter valued at approximately $33,000. Finally, Legacy Financial Group LLC bought a new position in Eli Lilly and Company in the third quarter valued at approximately $35,000. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of Eli Lilly and Company stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the transaction, the insider now owns 99,488,598 shares of the company’s stock, valued at approximately $64,177,109,911.86. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Price Performance

NYSE LLY opened at $726.31 on Friday. The firm’s 50 day moving average is $763.96 and its 200-day moving average is $659.59. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The company has a market capitalization of $690.11 billion, a PE ratio of 125.23, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $369.76 and a 12-month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period in the previous year, the business earned $2.09 EPS. The company’s revenue was up 28.1% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on LLY shares. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a report on Monday, April 15th. Bank of America upped their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research note on Wednesday, February 21st. Finally, The Goldman Sachs Group boosted their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.